Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
("Mediclinic", or the "Company" or the "Group")
24 July 2019
APPOINTMENT OF TOM SINGER AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR
Mediclinic announces that Tom Singer is to join its Board as an independent non-executive director with effect from 24 July 2019.
Dr Edwin Hertzog, Chairman of Mediclinic, commented:
"The Board is delighted to welcome Tom Singer as an independent non-executive director of the Company. His financial acumen and expertise in UK listed international hospitality and branded consumer businesses will be valuable additions to the Board's existing skillset."
Tom has extensive board experience and expertise in international branded consumer businesses and a thorough understanding of the UK listed environment. He has served as Chief Financial Officer of InterContinental Hotels Group PLC, a leading international hotel group, and British United Provident Association (BUPA), a provider of health insurance, care homes for the elderly and other health related services including private hospitals. Earlier in his career, Tom was Chief Financial Officer and Chief Operating Officer of William Hill PLC and Finance Director of Moss Bros PLC, having started his career in professional services spending a total of 12 years at Price Waterhouse and McKinsey. He currently serves as a non-executive director on the boards of DP Eurasia N.V., an operator of pizza restaurants in Turkey and Russia, and Liberty Living Group PLC, a provider of student accommodation in the UK.
Tom holds a degree in Economics and Accounting (University of Bristol), is a Chartered Accountant and has attended the Advanced Management Programme at INSEAD.
There are no disclosures required pursuant to paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority's Listing Rules in respect of this appointment. Tom Singer's fees will amount to £73 000 per annum, including the fee payable for membership of the Audit and Risk Committee as referred to below, which is in line with current independent non-executive directors.
CHANGES TO COMMITTEE MEMBERSHIPS
The Board also agreed to certain other changes to the membership of its committees. As announced on 15 November 2018, Desmond Smith, the Company's Senior Independent Director, will be retiring as a director of the Company upon the conclusion of the Company's Annual General Meeting being held today, at which point his memberships of all Board committees will cease. Alan Grieve will succeed Desmond Smith as Senior Independent Director of the Company and as Chairman of the Audit and Risk Committee. The Company also confirms the following Board committee changes:
Audit and Risk Committee:
With effect from 24 July 2019, Desmond Smith will step down as a member and Chairman of the Audit and Risk Committee. Alan Grieve will succeed Desmond Smith as Chairman of this Committee and Tom Singer will become a member of this committee from that date.
With effect from 24 July 2019, Desmond Smith will step down as a member of the Nomination Committee and will be succeeded on that committee by Alan Grieve.
About Mediclinic International plc
Mediclinic is an international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates.
The Group's core purpose is to enhance the quality of life by way of appropriate healthcare services.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.
Mediclinic comprises 77 hospitals, five sub-acute hospitals, 13 day case clinics and 21 outpatient clinics. Hirslanden operates 18 hospitals, two day case clinics and three outpatient clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operates 52 hospitals, five sub-acute hospitals and 9 day case clinics with more than 8 500 inpatient beds; and Mediclinic Middle East operates seven hospitals, two day case clinics and 21 outpatient clinics with more than 900 inpatient beds in the United Arab Emirates.
The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
+44 (0)20 3786 8181
Brett Pollard/Debbie Scott - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE Ltd sponsor: Rand Merchant Bank (A division of FirstRand Bank Ltd)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Quick facts: Mediclinic International Plc
Market Cap: £2.98 billion
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE